Clinical trial · Observational
A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer
A Study of Docetaxel and Lobaplatin vs. Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer
NCT01851746CI-TRIAL-00010251unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the effectiveness and security of lobaplatin combined with docetaxel in treatment of the sensitive recurrent ovarian cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Recurrent Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Evidence of the effectiveness and security of lobaplatin combined with docetaxel in treatment of the sensitive recurrent ovarian cancer.
- timeFrame
- from pre-chemotherapy to 4-6 weeks post-chemotherapy
- description
- Blood routine, urine routine, hepatic and kidney function, electrolyte, ECG, CT,MRI
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. age between 18 and 70 years old 2. singed the information consent form 3. Expected survival time \>3 months 4. Recurrence for at least 6 months after receiving initial platinum-based chemotherapy and without cytoreductive surgery indications. Exclusion Criteria: 1. Recurrence within 6 months after receiving initial platinum-based chemotherapy 2. without radiographic evidence for tumor recurrence 3. receiving other chemotherapy, hormone therapy, immunotherapy, or radiation therapy
References
Publications (0)
Data not yet available
No reference posted for this study.